Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)
TipRanks (Fri, 13-Sep 7:46 AM ET)
Buy Rating Affirmed for Seres Therapeutics Amid Strong Clinical Outcomes for SER-155
TipRanks (Fri, 13-Sep 7:01 AM ET)
TipRanks (Fri, 13-Sep 7:01 AM ET)
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Globe Newswire (Fri, 13-Sep 7:00 AM ET)
Globe Newswire (Thu, 12-Sep 7:00 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders
PRNewswire (Tue, 20-Aug 10:34 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders
PRNewswire (Tue, 13-Aug 6:24 PM ET)
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Globe Newswire (Tue, 13-Aug 7:00 AM ET)
Business Wire (Fri, 9-Aug 10:30 AM ET)
Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestl Health Science
Globe Newswire (Tue, 6-Aug 7:00 AM ET)
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Seres Therapeutics trades on the NASDAQ stock market under the symbol MCRB.
As of September 18, 2024, MCRB stock price declined to $1.05 with 2,780,253 million shares trading.
MCRB has a beta of 0.75, meaning it tends to be less sensitive to market movements. MCRB has a correlation of 0.01 to the broad based SPY ETF.
MCRB has a market cap of $160.00 million. This is considered a Micro Cap stock.
In the last 3 years, MCRB stock traded as high as $11.69 and as low as $.54.
The top ETF exchange traded funds that MCRB belongs to (by Net Assets): VTI, VXF, SCHA, VHT, SCHB.
MCRB stock has underperformed the market in the last year with a return of -63.3%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MCRB shares. However, MCRB has outperformed the market in the last 3 month and 2 week periods, returning +56.5% and +34.0%, while SPY returned +2.9% and +1.7%, respectively. This indicates MCRB has been having a stronger performance recently.
MCRB support price is $1.01 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCRB stock will trade within this expected range on the day.